Genfit SA Reports Revenue Decline and Net Loss

Genfit SA ( (GNFTF) ) has released its Q2 earnings. Here is a breakdown of the information Genfit SA presented to its investors.

Genfit SA is a French biopharmaceutical company focused on the discovery and development of innovative drug candidates and diagnostic solutions, primarily targeting metabolic and liver diseases with unmet medical needs. In its latest earnings report for the first half of 2025, Genfit reported a significant decrease in revenue and a net loss, attributed to various operational and financial challenges. Key financial highlights include a drop in revenue to €33.5 million from €59 million in the same period last year, alongside a net loss of €10 million compared to a net profit of €30 million previously. The company also faced increased research and development expenses, particularly related to its VS-01 product, and a substantial rise in financial charges due to the royalty financing agreement. Despite these challenges, Genfit secured a milestone payment from Ipsen for its drug Iqirvo®, approved in Italy, which contributed €26.5 million to its revenue. Looking ahead, Genfit plans to focus on its UCD program following the discontinuation of its VS-01 program due to safety concerns. The company remains committed to advancing its pipeline and exploring strategic opportunities to enhance shareholder value.